News & CommentDNA Patents

Patent Office Faces 90-Year Backlog

+ See all authors and affiliations

Science  03 May 1996:
Vol. 272, Issue 5262, pp. 643
DOI: 10.1126/science.272.5262.643a

Summary

While some academic researchers have been signing a pledge not to patent raw DNA sequences, companies that specialize in sequencing DNA—chiefly Incyte Pharmaceuticals of Palo Alto, California, and Human Genome Sciences of Rockville, Maryland—have been channeling data from their automated sequencers into the Patent and Trademark Office (PTO) at a torrential rate. Applications covering more than 400,000 sequences have been filed, and the PTO is seeking help in dealing with the flood

Related Content